Biocontainment strategies for live lactic acid bacteria vaccine vectors

Abstract

Stability is an important issue when engineering bacteria for use as live vaccine  vectors. For the majority of live bacterial vaccines, the antigen-encoding gene is either plasmid located or integrated into the chromosome. Regardless, several safety concerns can be raised for both instances. One concern when using plasmid-encoded antigens is the transfer of antibiotic resistance markers. Alternatively, for chromosomal integrated antigens however, the concern focuses on the spread and possible release of genetically modified  microorganisms (GMM) into the environment which is problematic. Their recombinant nature calls for a proper bio containment strategy to be implemented or in place before any realistic attempt at releasing a live bacterial vaccine. No examples of human bacterial vaccines causing problems among animals have been found in the literature but the possibility exists and has to be both tested and evaluated before release of a live bacterial vaccine. The ideal GMM for use in humans should therefore contain the minimal amount of foreign DNA and must not include an antibiotic resistance marker. Furthermore, the possibilities of transgene horizontal transfer must be minimized, and GMM lethality for biocontainment should be achieved in an unconfined environment.

 

Commentary to:

Efficacy of a lactococcus lactis ΔpyrG vaccine delivery platform expressing chromosomally integrated hly from listeria monocytogenes

Mohammed Bahey-El-Din , Pat G. Casey, Brendan T. Griffin and Cormac G.M. Gahan